APA

Moy B., Neven P., Lebrun F., Bellet M., Xu B., Sarosiek T., Chow L., Goss P., Zacharchuk C., Leip E., Turnbull K., Bardy-Bouxin N., Duvillié L. & Láng I. (20150112). Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. : The oncologist.

Chicago

Moy Beverly, Neven Patrick, Lebrun Fabienne, Bellet Meritxell, Xu Binghe, Sarosiek Tomasz, Chow Louis, Goss Paul, Zacharchuk Charles, Leip Eric, Turnbull Kathleen, Bardy-Bouxin Nathalie, Duvillié Ladan and Láng István. 20150112. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. : The oncologist.

Harvard

Moy B., Neven P., Lebrun F., Bellet M., Xu B., Sarosiek T., Chow L., Goss P., Zacharchuk C., Leip E., Turnbull K., Bardy-Bouxin N., Duvillié L. and Láng I. (20150112). Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. : The oncologist.

MLA

Moy Beverly, Neven Patrick, Lebrun Fabienne, Bellet Meritxell, Xu Binghe, Sarosiek Tomasz, Chow Louis, Goss Paul, Zacharchuk Charles, Leip Eric, Turnbull Kathleen, Bardy-Bouxin Nathalie, Duvillié Ladan and Láng István. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. : The oncologist. 20150112.